A Neural Mechanism for Nonconscious Activation of Conditioned Placebo and Nocebo Responses [PDF]
Fundamental aspects of human behavior operate outside of conscious awareness. Yet, theories of conditioned responses in humans, such as placebo and nocebo effects on pain, have a strong emphasis on conscious recognition of contextual cues that trigger the response.
Karin B. Jensen+6 more
openalex +5 more sources
Conscious Expectation and Unconscious Conditioning in Analgesic, Motor, and Hormonal Placebo/Nocebo Responses [PDF]
The placebo and nocebo effect is believed to be mediated by both cognitive and conditioning mechanisms, although little is known about their role in different circumstances. In this study, we first analyzed the effects of opposing verbal suggestions on experimental ischemic arm pain in healthy volunteers and on motor performance in Parkinsonian ...
Fabrizio Benedetti+5 more
openalex +5 more sources
Placebo and Nocebo Responses in Pharmacological Trials of Tic Disorders: A Meta‐Analysis [PDF]
AbstractBackgroundClinical trials of new drugs for tic disorders (TD) often fail to yield positive results. Placebo and nocebo responses play a vital role in interpreting the outcomes of randomized controlled trials (RCTs), yet these responses in RCTs of TD remain unexplored.ObjectiveThe aim was to assess the magnitude of placebo and nocebo responses ...
Simeng Wang+9 more
openalex +3 more sources
A neural mechanism of direct and observational conditioning for placebo and nocebo responses [PDF]
Classical theories suggest placebo analgesia and nocebo hyperalgesia are based on expectation and conditioned experience. Whereas the neural mechanism of how expectation modulates placebo and nocebo effects during pain anticipation have been extensively studied, little is known about how experience may change brain networks to produce placebo and ...
Yiheng Tu+7 more
openalex +5 more sources
A large number of unwanted adverse events and symptoms reported by patients in clinical trials are not caused by the drug provided, since most of adverse events also occur in corresponding placebo groups. These nocebo effects also play a major role in drug discontinuation in clinical practice, negatively affecting treatment efficacy as well as patient ...
Laura Wendt+8 more
openalex +6 more sources
BACKGROUND: Multiple System Atrophy (MSA) is a rapidly progressive and fatal neurodegenerative disease, with no effective treatment. Estimating the placebo and nocebo responses will help better design and interpret clinical trials. Objective: To estimate
Adelina Amorim+3 more
openalex +2 more sources
Social observation is one of the main ways to gain experience. Similar to first-person experience, observational experience affects the effectiveness of subsequent treatments. Yet, it is still undetermined whether the influence of social observation on placebo and nocebo effects to subsequent treatments remains even if related experience occurred a few
Huijuan Zhang+4 more
openalex +8 more sources
Development of a personalized digital biomarker of vaccine-associated reactogenicity using wearable sensors and digital twin technology [PDF]
Background Effective response to vaccination requires activation of the innate immune system, triggering the synthesis of inflammatory cytokines. The degree of subjective symptoms related to this, referred to as reactogenicity, may predict their eventual
Steven R. Steinhubl+10 more
doaj +2 more sources
Interpersonal physiological and psychological synchrony predict the social transmission of nocebo hyperalgesia between individuals [PDF]
Witnessing another’s pain can heighten pain in the observer. However, research has focused on the observer’s intrapersonal experience. Here, a social transmission-chain explored the spread of socially-acquired nocebo hyperalgesia.
Rodela Mostafa+5 more
doaj +2 more sources
Discontinuation of Fumaric Acid Esters is Affected by Depressive Symptomatology: A Retrospective Analysis [PDF]
Fumaric acid esters (FAEs) remain a widespread therapy option for moderate-to-severe psoriasis. However, drug survival of FAEs is limited by adverse events (AEs) or inadequate treatment response.
Frederik Krefting+3 more
doaj +2 more sources